IMMUNOLOGICAL MECHANISMS IN CANCER PROGRAM The Immunological Mechanisms in Cancer Program comprises nineteen investigators from six academic departments. The primary objectives of the IMC Program are 1) to create a strong, intellectual and highly interactive scientific environment in which the functioning of the immune system as it relates to the cancer problem can be imaginatively and efficiently investigated;and 2) to foster, through intra- and inter-programmatic collaboration, the translation of the knowledge gained from these studies to the development of approaches for the prevention, diagnosis and treatment of cancer. The interests of the faculty are varied but the program is unified by four main themes: 1) to improve our understanding of the molecular and cellular basis for the development hematopoietic malignancies;2) to elucidate the nature of tumor antigen recognition and response to tumors by the immune system, thereby supporting development of immunotherapeutic approaches to cancer;3) to investigate the role of viruses in the development of cancer and cancer therapies;and 4) to create improvements in bone marrow transplantation approaches for the treatment of hematopoietic malignancies. Of the nineteen program members, eighteen have been funded through peer-reviewed awards. Current NCI and total peer review support for this program total approximately 1.8 and 8.2 million dollars, respectively. In the previous funding period, program members published 150 cancer-relevant papers, 14 and 20 percent of which resulted from intra, and inter-programmatic collaborations, respectively. Collaborations between members of this and other programs in the Kimmel Cancer Center have contributed to the production of reagents and analysis of preclinical models for testing novel therapies that have resulted in clinical trials. The expertise and the insight provided by members of the program is of increasing importance to the center for the definition of both functional and molecular aspects of the host-tumor interaction. Further development of the program is planned in the areas of tumor immunology and the immunobiology of dendritic cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-13
Application #
8378859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
13
Fiscal Year
2012
Total Cost
$25,633
Indirect Cost
$8,982
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Mikkilineni, Lekha; Whitaker-Menezes, Diana; Domingo-Vidal, Marina et al. (2017) Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. Semin Oncol 44:218-225
Wirblich, Christoph; Coleman, Christopher M; Kurup, Drishya et al. (2017) One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J Virol 91:
Weinberg, David S; Lin, Jieru E; Foster, Nathan R et al. (2017) Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prev Res (Phila) 10:345-354
Monti, Daniel; Sotgia, Federica; Whitaker-Menezes, Diana et al. (2017) Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer. Semin Oncol 44:226-232
Curry, Joseph; Johnson, Jennifer; Tassone, Patrick et al. (2017) Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope 127:1808-1815
Mitra, Ramkrishna; Chen, Xi; Greenawalt, Evan J et al. (2017) Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun 8:1604
Paolillo, Carmela; Mu, Zhaomei; Rossi, Giovanna et al. (2017) Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clin Cancer Res 23:6086-6093
Overmiller, Andrew M; Pierluissi, Jennifer A; Wermuth, Peter J et al. (2017) Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. FASEB J 31:3412-3424
Cheng, Hanyin; Chua, Vivian; Liao, Connie et al. (2017) Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther 16:516-528
Jiang, Wei; Dulaimi, Essel; Devarajan, Karthik et al. (2017) Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. Oncotarget 8:37423-37434

Showing the most recent 10 out of 777 publications